Dongin (Donoven) Kim, Ph.D.
Prof,Asst
Pharmaceutical Sciences
Phone (405) 271-6593 x 47473
Office COP200
Email dongin-kim@ou.edu
Publications & Presentations
- 46. Dasari M, Lee S, Sy J, Kim D, Lee S, Brown M, Davis M, Murthy N. Hoechst-IR: an imaging agent that detects necrotic tissue in vivo by binding extracellular DNA. Organic letters. 2010; 12 : 3300-3
47. Kim D, Gao Z G, Lee E S, Bae Y H. In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Molecular pharmaceutics. 2009; 6 : 1353-62
48. Oh K T, Kim D, You H H, Ahn Y S, Lee E S. pH-sensitive properties of surface charge-switched multifunctional polymeric micelle. International journal of pharmaceutics. 2009; 376 : 134-40
49. Kim D, Lee E S, Oh K T, Gao Z G, Bae Y H. Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small (Weinheim an der Bergstrasse, Germany). 2008; 4 : 2043-50
50. Gao Z, Lee D, Kim D, Bae Y H. Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice. Journal of Drug Targeting. 2008; 13 : 391-397
Grants
- 6. Lymphatics and lymphangiogenesis in kidney function and inflammation. NIH. Start Date: 2019. End Date: 2024.
7. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.
8. Preclinical assessment of exosomal drug delivery system using innovative tumor mouse model. Misc Non-Federal. Start Date: 2024. End Date: 2024.
9. Role of Renal Lymphatics in Blood Pressure Regulation. NIH. Start Date: 2018. End Date: 2023.
10. Cancer exosome mediated antibody production for active tumor targeting treatment. Non-federal. Start Date: 2022. End Date: 2023.
Awards and Honors
no results
Education
- 1. Degree: Ph D. University of Utah. Date: 2009.
2. Degree: MS. University of Florida. Date: 2002.
3. Degree: BS. Ajou University. Date: 1999.
Administrative Assignments
no results